Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)
Stopped early · Phase 2
Conditions studied: Muscle Weakness
In brief
The main purpose for this study is to provide access to 3,4 DAP, a drug which has demonstrated to be effective in treating weakness associated with Lambert-Eaton Myasthenic Syndrome. LEMS is a rare autoimmune cause of a defect in neuromuscular transmission. The disorder is clinically characterized by fluctuating muscle weakness, hyporeflexia and autonomic dysfunction.
Key facts
- Study ID
- NCT02090725
- Run by
- Jeffrey A. Cohen, MD
- People needed
- 4
- Starts
- 2004-02-01
- Expected to finish
- 2018-11-28
- Last updated by the study team
- 2019-05-21
Who can join
Age: 45 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.